Exercise Exercise influences far more than calorie expenditure
Back in 2024, research presented at the European Congress on Obesity found that people who gradually reduced their GLP-1s dose to zero over the course of nine weeks were able to maintain a stable body weight in the first 26 weeks post-GLP-1s
Rotate between sites and specific locations within each site
If your doctor can document either of these conditions, your path to coverage becomes significantly clearer
Maybe two
Pharmaceuticals GLP-1 Receptor Agonist Market GLP-1 Receptor Agonist Market Size, Trends, Share, Growth, and Regional Forecast, 2026 to 2033 GLP-1 Receptor Agonist Market by Product (Ozempic, Wegovy, Rybelsus, Victoza, Zepbound, Saxenda, Trulicity, Mounjaro, Others), Indication (Type 2 Diabetes mellitus, Obesity, Others), Route of Administration (Parenteral, Oral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Analysis from 2026 to 2033 December 2025 210 Pages Author : Abhijeet Surwase GLP-1 Receptor Agonist Market Share and Trends Analysis The global GLP-1 receptor agonist market size is estimated to grow from US$ 74.4 billion in 2026 to US$ 232.8 billion by 2033